Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TXB4-PD-L1
- Development stage
- Preclinical
- Lead developer
- Ossianix
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
TXB4-PD-L1 is a preclinical bispecific fusion protein developed by Ossianix. It consists of the brain-penetrating single-domain shark antibody (VNAR) shuttle TXB4, which targets transferrin receptor 1 (TfR1 / CD71), fused to the anti-PD-L1 monoclonal antibody durvalumab (MEDI4736). By leveraging receptor-mediated transcytosis (or other brain-entry mechanisms) via TfR1, TXB4-PD-L1 is designed to cross the blood-brain barrier (BBB) and deliver the immune checkpoint inhibitor durvalumab into the brain parenchyma. This approach aims to enhance the therapeutic efficacy of PD-L1 blockade in central nervous system (CNS) malignancies, such as primary central nervous system lymphoma (PCNSL) or brain metastases, while minimizing systemic exposure and side effects.
- Other names
- TXB4-durvalumabTXB-4-durvalumabTXB 4-durvalumabTXB4-MEDI4736TXB-4-MEDI4736TXB 4-MEDI4736
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on TXB4-PD-L1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TXB4-PD-L1.